On the other hand, CSF biomarkers, especially Aβ 1‐40 (Aβ40), Aβ42, total tau (t‐Tau), and phosphorylated tau‐181 (p‐Tau181), can be used in the AD field to evaluate the level of different AD pathology‐related biological analytes and are more accessible and less expensive than amyloid PET. Here, MAPT is linked to Alzheimer disease.